Charles Schwab Investment Management Inc. Has $4.69 Million Stock Position in USANA Health Sciences, Inc. $USNA

Key Points

• Charles Schwab Investment Management Inc. increased its stake in USANA Health Sciences, Inc. by 23.5%, acquiring an additional 33,141 shares in the first quarter, bringing its total ownership to 173,997 shares valued at $4.69 million.
• Wells Fargo and Barclays also raised their stakes in USANA, highlighting a trend of increased investments from hedge funds as institutional investors now hold 54.25% of the company's stock.
• USANA Health Sciences recently reported a quarterly earnings per share of $0.74, exceeding analysts’ expectations of $0.54, and anticipates a FY 2025 earnings guidance between $2.350-3.000 EPS.

Charles Schwab Investment Management Inc. grew its holdings in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 23.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 173,997 shares of the company's stock after purchasing an additional 33,141 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.93% of USANA Health Sciences worth $4,693,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE boosted its position in USANA Health Sciences by 13.1% during the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock valued at $124,000 after acquiring an additional 535 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in USANA Health Sciences by 7.1% in the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after purchasing an additional 606 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after acquiring an additional 771 shares during the period. Versant Capital Management Inc raised its holdings in USANA Health Sciences by 542.5% in the 1st quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after acquiring an additional 971 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in USANA Health Sciences by 15.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock worth $260,000 after buying an additional 985 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $36.00.

Insider Buying and Selling

In other news, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. This represents a 27.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,073 shares of company stock valued at $151,982. 0.63% of the stock is currently owned by company insiders.

USANA Health Sciences Stock Performance

USNA traded up $0.54 during trading hours on Friday, reaching $31.92. The company's stock had a trading volume of 77,270 shares, compared to its average volume of 102,809. USANA Health Sciences, Inc. has a 52 week low of $23.10 and a 52 week high of $41.83. The firm has a market cap of $583.23 million, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.01 and a beta of 0.61. The company's 50-day moving average is $31.14 and its 200-day moving average is $29.56.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.20. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%.The company had revenue of $235.85 million during the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Equities analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.